- Conditions
- Lafora Disease
- Interventions
- ION283
- Genetic
- Lead sponsor
- Berge Minassian
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Peripheral Neuropathy, Neuro-Degenerative Disease, Neuromuscular Diseases
- Interventions
- Not listed
- Lead sponsor
- Elpida Therapeutics SPC
- Industry
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 3
- States / cities
- San Francisco, California • Iowa City, Iowa • Dallas, Texas
- Conditions
- Spasticity, Muscle, Microcephaly, Intellectual Deficiency, Growth Retardation, SPG50, Spastic Paraplegia
- Interventions
- MELPIDA
- Biological
- Lead sponsor
- Elpida Therapeutics SPC
- Industry
- Eligibility
- 4 Months to 10 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Hereditary Spastic Paraplegia Type 50
- Interventions
- MELPIDA
- Genetic
- Lead sponsor
- Elpida Therapeutics SPC
- Industry
- Eligibility
- 4 Months to 72 Months
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Charcot-Marie-Tooth Disease Type 4J
- Interventions
- ELP-02
- Genetic
- Lead sponsor
- Elpida Therapeutics SPC
- Industry
- Eligibility
- 3 Years to 20 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Iowa City, Iowa